- ICH GCP
- Rejestr badań klinicznych w USA
- Badanie kliniczne NCT05921994
Długoterminowe obserwacyjne, prospektywne, wieloośrodkowe badanie w celu zebrania w rzeczywistej populacji danych dotyczących schematu leczenia secukinumAb u dorosłych pacjentów z umiarkowanym do ciężkiego ropnym zapaleniem apokrynowych gruczołów potowych. (ANIMA)
Długoterminowe obserwacyjne, prospektywne, wieloośrodkowe badanie w celu zebrania w rzeczywistej populacji danych dotyczących schematu leczenia secukinumAb u dorosłych pacjentów z umiarkowanym do ciężkiego zapaleniem ropnych gruczołów potowych (HS) (ANIMA)
The purpose of this observational, prospective, non-interventional, multicenter, open-label, single arm study in Hidradenitis suppurativa (HS) is to assess the treatment pattern of secukinumab in a flexible dosing regimen and decision influencing factors for flexible dosing in a real-world population over 2 years.
Przegląd badań
Status
Warunki
Interwencja / Leczenie
Szczegółowy opis
The study will collect data from patients during routine secukinumab treatment and will be representative of the real-world patient population eligible for secukinumab treatment in Germany.
In order to attain widespread representation of health care practices related to the use of secukinumab in the approved indication of moderate to severe HS, a broad spectrum of dermatology practices and clinics who are treating patients with HS across Germany will be included.
Typ studiów
Zapisy (Rzeczywisty)
Kontakty i lokalizacje
Lokalizacje studiów
-
-
-
Aachen, Niemcy, 52064
- Novartis Investigative Site
-
Ahaus, Niemcy, 48683
- Novartis Investigative Site
-
Annaberg-Buchholz, Niemcy, 09456
- Novartis Investigative Site
-
Bad Steben, Niemcy, 95138
- Novartis Investigative Site
-
Baden-Baden, Niemcy, 76530
- Novartis Investigative Site
-
Berlin, Niemcy, 12159
- Novartis Investigative Site
-
Berlin, Niemcy, 13595
- Novartis Investigative Site
-
Bielefeld, Niemcy, 33647
- Novartis Investigative Site
-
Bochum, Niemcy, 44791
- Novartis Investigative Site
-
Bonn, Niemcy, 53105
- Novartis Investigative Site
-
Brandenburg, Niemcy, 14776
- Novartis Investigative Site
-
Bremen, Niemcy, 28359
- Novartis Investigative Site
-
Buxtehude, Niemcy, 21614
- Novartis Investigative Site
-
Bückeburg, Niemcy, 31675
- Novartis Investigative Site
-
Chemnitz, Niemcy, 09117
- Novartis Investigative Site
-
Chemnitz, Niemcy, 09113
- Novartis Investigative Site
-
Cologne, Niemcy, 51065
- Novartis Investigative Site
-
Delitzsch, Niemcy, 04509
- Novartis Investigative Site
-
Dessau, Niemcy, 06847
- Novartis Investigative Site
-
Dorsten, Niemcy, 46282
- Novartis Investigative Site
-
Dortmund, Niemcy, 44137
- Novartis Investigative Site
-
Dresden, Niemcy, 01309
- Novartis Investigative Site
-
Düren, Niemcy, 52349
- Novartis Investigative Site
-
Emsdetten, Niemcy, 48282
- Novartis Investigative Site
-
Erlangen, Niemcy, 91054
- Novartis Investigative Site
-
Falkenberg, Niemcy, 04895
- Novartis Investigative Site
-
Falkensee, Niemcy, 14612
- Novartis Investigative Site
-
Freising, Niemcy, 85354
- Novartis Investigative Site
-
Geilenkirchen, Niemcy, 52511
- Novartis Investigative Site
-
Gera, Niemcy, 07548
- Novartis Investigative Site
-
Gernsbach, Niemcy, 76593
- Novartis Investigative Site
-
Gladbeck, Niemcy, 45964
- Novartis Investigative Site
-
Großenhain, Niemcy, 01558
- Novartis Investigative Site
-
Hamburg, Niemcy, 20246
- Novartis Investigative Site
-
Hamburg, Niemcy, 22143
- Novartis Investigative Site
-
Hanover, Niemcy, 30159
- Novartis Investigative Site
-
Haslach im Kinzigtal, Niemcy, 77716
- Novartis Investigative Site
-
Hofgeismar, Niemcy, 34369
- Novartis Investigative Site
-
Jena, Niemcy, 07743
- Novartis Investigative Site
-
Jülich, Niemcy, 52428
- Novartis Investigative Site
-
Karlsruhe, Niemcy, 76133
- Novartis Investigative Site
-
Kempen, Niemcy, 47906
- Novartis Investigative Site
-
Lübeck, Niemcy, 23538
- Novartis Investigative Site
-
Magdeburg, Niemcy, 39120
- Novartis Investigative Site
-
Magdeburg, Niemcy, 39104
- Novartis Investigative Site
-
Mainz, Niemcy, 55116
- Novartis Investigative Site
-
Marburg, Niemcy, 35043
- Novartis Investigative Site
-
Minden, Niemcy, 32429
- Novartis Investigative Site
-
Mönchengladbach, Niemcy, 41063
- Novartis Investigative Site
-
Neu Wulmstorf, Niemcy, 21629
- Novartis Investigative Site
-
Nuremberg, Niemcy, 90419
- Novartis Investigative Site
-
Oberasbach, Niemcy, 90522
- Novartis Investigative Site
-
Oelde, Niemcy, 59302
- Novartis Investigative Site
-
Peitz, Niemcy, 03185
- Novartis Investigative Site
-
Potsdam, Niemcy, 14469
- Novartis Investigative Site
-
Remscheid, Niemcy, 42897
- Novartis Investigative Site
-
Selters, Niemcy, 56242
- Novartis Investigative Site
-
Simmern, Niemcy, 55469
- Novartis Investigative Site
-
Soest, Niemcy, 59494
- Novartis Investigative Site
-
Stolberg, Niemcy, 52222
- Novartis Investigative Site
-
Unna, Niemcy, 59423
- Novartis Investigative Site
-
Wittlich, Niemcy, 54316
- Novartis Investigative Site
-
Wuppertal, Niemcy, 42103
- Novartis Investigative Site
-
-
Baden-Wurttemberg
-
Freiburg im Breisgau, Baden-Wurttemberg, Niemcy, 79068
- Novartis Investigative Site
-
Rheinstetten, Baden-Wurttemberg, Niemcy, 76287
- Novartis Investigative Site
-
-
Bavaria
-
Haßfurt, Bavaria, Niemcy, 97437
- Novartis Investigative Site
-
Kulmbach, Bavaria, Niemcy, 95326
- Novartis Investigative Site
-
Lauf an der Pegnitz, Bavaria, Niemcy, 91207
- Novartis Investigative Site
-
Nuremberg, Bavaria, Niemcy, 90402
- Novartis Investigative Site
-
-
Brandenburg
-
Panketal, Brandenburg, Niemcy, 16341
- Novartis Investigative Site
-
-
Free and Hanseatic City of Hamburg
-
Hamburg, Free and Hanseatic City of Hamburg, Niemcy, 22549
- Novartis Investigative Site
-
-
Lower Saxony
-
Lingen, Lower Saxony, Niemcy, 49809
- Novartis Investigative Site
-
-
Mecklenburg-Vorpommern
-
Bergen auf Rügen, Mecklenburg-Vorpommern, Niemcy, 18528
- Novartis Investigative Site
-
Kröpelin, Mecklenburg-Vorpommern, Niemcy, 18236
- Novartis Investigative Site
-
-
North Rhine-Westphalia
-
Krefeld, North Rhine-Westphalia, Niemcy, 47798
- Novartis Investigative Site
-
-
Rhineland-Palatinate
-
Mainz, Rhineland-Palatinate, Niemcy, 55128
- Novartis Investigative Site
-
-
Saxony
-
Dresden, Saxony, Niemcy, 01307
- Novartis Investigative Site
-
Leipzig, Saxony, Niemcy, 04207
- Novartis Investigative Site
-
Leipzig, Saxony, Niemcy, 04289
- Novartis Investigative Site
-
-
Saxony-Anhalt
-
Wittenberg, Saxony-Anhalt, Niemcy, 06886
- Novartis Investigative Site
-
-
Kryteria uczestnictwa
Kryteria kwalifikacji
Wiek uprawniający do nauki
Akceptuje zdrowych ochotników
Płeć kwalifikująca się do nauki
Metoda próbkowania
Badana populacja
patients, being treated for HS with secukinumab according to the summary of product characteristics (SmPC), after the approval of secukinumab has been granted in this indication.
Opis
Inclusion Criteria:
Patients eligible for inclusion in this study have to fulfill all of the following criteria at enrollment:
- Patients who provide written informed consent to participate in the study
- Male and female patients with ≥18 years of age
- Diagnosis of clinically unequivocal moderate to severe HS
- Patients for whom a therapy with secukinumab is medically indicated
- Documented decision for treatment with marketed secukinumab regardless of this noninterventional study
- Treatment with secukinumab according to the latest version of SmPC
- Initial treatment with marketed secukinumab planned for up to 1 week before the baseline visit
Exclusion Criteria:
Patients fulfilling any of the following criteria at enrollment are not eligible for inclusion in this study. No additional exclusions may be applied by the investigator, in order to ensure that the study population will be representative of all eligible patients:
- Patients who have any contraindications, such as a history of or active inflammatory bowel disease (Crohn´s disease, ulcerative colitis), and are not eligible for treatment with secukinumab according to the SmPC
- Any medical or psychological condition in the treating physician's opinion which may prevent the patient from the study participation
- Simultaneous participation in any investigational trial or simultaneous participation in another Novartis-sponsored non-interventional study with secukinumab
- Previous exposure to IL-17 inhibitors
- For biologic-naïve patients, previous exposure to another biologic drug, such as anti-TNF-α inhibitors
Plan studiów
Jak projektuje się badanie?
Szczegóły projektu
- Modele obserwacyjne: COHORT
- Perspektywy czasowe: PROSPECTIVE
Kohorty i interwencje
Grupa / Kohorta |
Interwencja / Leczenie |
|---|---|
|
secukinumab
Patients being treated for HS with secukinumab according to the summary of product characteristics (SmPC), after the approval of secukinumab has been granted in this indication. |
Prospective observational study. There is no treatment allocation. Patients administered secukinumab by prescription and administered according to the SmPC. |
Co mierzy badanie?
Podstawowe miary wyniku
Miara wyniku |
Opis środka |
Ramy czasowe |
|---|---|---|
|
Proportion of patients receiving up-titration
Ramy czasowe: Up to 24 months
|
Proportion of patients receiving up-titration (q4w-to-q2w) |
Up to 24 months
|
|
Proportion of patients receiving down-titration
Ramy czasowe: Up to 24 months
|
Proportion of patients receiving down-titration (q2w-to-q4w) |
Up to 24 months
|
|
Time to up-titration and down-titration
Ramy czasowe: Up to 2 years
|
Time to up-titration and down-titration |
Up to 2 years
|
|
Duration of q4w treatment with secukinumab after dose reduction
Ramy czasowe: Up to 2 years
|
Duration of q4w treatment with secukinumab after dose reduction |
Up to 2 years
|
|
Proportion of patients who receive more than one up-and/or down titration
Ramy czasowe: Up to 24 months
|
Proportion of patients who receive more than one up-and/or down titration |
Up to 24 months
|
|
Proportion of patients receiving HS-specific concomitant treatments in combination with secukinumab
Ramy czasowe: Up to 2 years
|
Proportion of patients receiving HS-specific concomitant treatments in combination with secukinumab |
Up to 2 years
|
|
Number and type of surgical interventions
Ramy czasowe: Up to 2 years
|
Number and type of surgical interventions
|
Up to 2 years
|
|
Proportion of patients achieving 55% reduction in IHS4 (IHS4-55)
Ramy czasowe: Up to 24 months
|
The IHS4 is an exclusively physician-based, clinical scoring system for dynamic assessment of HS severity. HS severity is calculated based on the number of lesions multiplied by their respective score: the IHS4 score (points) = (number of nodules multiplied by 1) + (number of abscesses multiplied by 2) + [number of draining tunnels (fistulae/sinuses) multiplied by 4]. A score of 3 or less signifies mild HS, a score of 4-10 signifies moderate HS and a score of 11 or higher signifies severe HS |
Up to 24 months
|
|
mean change of International Hidradenitis Suppurativa Severity Score System (IHS4)
Ramy czasowe: Up to 24 months
|
The IHS4 is an exclusively physician-based, clinical scoring system for dynamic assessment of HS severity. HS severity is calculated based on the number of lesions multiplied by their respective score: the IHS4 score (points) = (number of nodules multiplied by 1) + (number of abscesses multiplied by 2) + [number of draining tunnels (fistulae/sinuses) multiplied by 4]. A score of 3 or less signifies mild HS, a score of 4-10 signifies moderate HS and a score of 11 or higher signifies severe HS |
Up to 24 months
|
|
Proportion of patients achieving a 5-point reduction of their Dermatology Life Quality Index (DLQI) questionnaire
Ramy czasowe: Up to 24 months
|
The DLQI is a 10-item general dermatology disability index designed to assess health-related quality of life (HRQoL) in adult subjects with skin diseases such as eczema, psoriasis, acne, and viral warts. The measure is self-administered and includes domains of daily activities, leisure, personal relationships, symptoms and feelings, treatment, and work/school. Each item has four response categories ranging from 0 (not at all) to 3 (very much). "Not relevant" is also a valid response and is scored as 0. The DLQI total score is a sum of the 10 questions. Scores range from 0 to 30, with higher scores indicating greater HRQoL impairment. |
Up to 24 months
|
|
Mean reduction of Abscesses and inflammatory nodules (AN) count
Ramy czasowe: Up to 24 months
|
Mean reduction of Abscesses and inflammatory nodules (AN) count |
Up to 24 months
|
|
Proportion of patients achieving a 30% reduction of pain Numerical Rating scale 30 (NRS30)
Ramy czasowe: Up to 24 months
|
The NRS is a segmented numeric version of the visual analog scale (VAS) in which a respondent selects a whole number (0-10 integers) that best reflects the intensity of their pain ranging from 0 (no skin pain) to 10 (skin pain as bad as you can imagine). To assess this, the patient should concentrate on the pain that his/her skin lesions generate. The Patient's Global Assessment of Skin Pain - NRS will be completed by the subject electronically via a web-based application or in paper form. |
Up to 24 months
|
Współpracownicy i badacze
Sponsor
Śledczy
- Dyrektor Studium: Novartis Pharmaceuticals, Novartis Pharmaceuticals
Daty zapisu na studia
Główne daty studiów
Rozpoczęcie studiów (Rzeczywisty)
Zakończenie podstawowe (Szacowany)
Ukończenie studiów (Szacowany)
Daty rejestracji na studia
Pierwszy przesłany
Pierwszy przesłany, który spełnia kryteria kontroli jakości
Pierwszy wysłany (Rzeczywisty)
Aktualizacje rekordów badań
Ostatnia wysłana aktualizacja (Rzeczywisty)
Ostatnia przesłana aktualizacja, która spełniała kryteria kontroli jakości
Ostatnia weryfikacja
Więcej informacji
Terminy związane z tym badaniem
Słowa kluczowe
Dodatkowe istotne warunki MeSH
Inne numery identyfikacyjne badania
- CAIN457MDE01
Plan dla danych uczestnika indywidualnego (IPD)
Planujesz udostępniać dane poszczególnych uczestników (IPD)?
Te informacje zostały pobrane bezpośrednio ze strony internetowej clinicaltrials.gov bez żadnych zmian. Jeśli chcesz zmienić, usunąć lub zaktualizować dane swojego badania, skontaktuj się z register@clinicaltrials.gov. Gdy tylko zmiana zostanie wprowadzona na stronie clinicaltrials.gov, zostanie ona automatycznie zaktualizowana również na naszej stronie internetowej .